Results 131 to 140 of about 630,325 (166)

The Effect of FcRn Binding on Ocular Disposition of Monoclonal Antibodies. [PDF]

Antibodies (Basel)
Naware S, Kulkarni S, Salvi S, Patel D, Shah DK.   +4 more
europepmc   +1 more source

Management of thyroid disorders: from autoimmunity to malignancy - novel insights from precision medicine: <i>How to manage thyroid diseases: from autoimmunity to malignancy</i> Special Issue. [PDF]

Drugs Context
Saltiki K, Effraimidis G.
europepmc   +1 more source

A case report of sequential efgartigimod and rituximab treatment for tSNMG. [PDF]

Front Immunol
Xie H, Pan TT, Zhang L.
europepmc   +1 more source

CSL305: A Dual Functional Therapeutic Antibody Targeting Complement C2 and FcRn. [PDF]

Int J Mol Sci
Wymann S, Morales RAV, Toh WH, Remlinger J, Guse K, Ghai R, Pestel S, Sansome G, Chen CG, Rayzman V, Chia J, Quek AJ, Gorman MA, Halder P, Powers G, Ruthsatz T, Parker MW, Rowe T, Vyas S, Verhagen AM, Hardy MP.   +20 more
europepmc   +1 more source

Assessing efgartigimod dosing patterns and Myasthenia Gravis Activities of Daily Living outcomes in clinical practice: results from a large patient support program database. [PDF]

Front Neurol
Narayanaswami P, Smith AG, Bhavaraju-Sanka R, Qi C, Jefferson M, Aldridge J, Heerlein K, Gelinas D, Dhingra M, Menon RR, Sato M, Wolfe GI.   +11 more
europepmc   +1 more source

Efgartigimod as Rescue Therapy for PD-1 Inhibitor-Associated Myasthenia Gravis, Myocarditis, and Myositis (MMM) Syndrome: A 2-Case Report and Literature Review. [PDF]

Am J Case Rep
Liu ZH, Duan LM, Fang XZ, Jiang W, Sun SW, Shang Y, Huang CL, Yuan Y.   +7 more
europepmc   +1 more source

Progress in the Treatment of Refractory Myasthenia Gravis. [PDF]

Rev Neurol
Liu D, Mao J, Song J, Wang M.
europepmc   +1 more source

Clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double‑blind, placebo‑controlled, phase 3 trial (ADAPT). [PDF]

J Neurol
Howard JF, Saccà F, Hoffmann S, Attarian S, De Bleecker JL, Beauchamp J, Brauer E, Kerstens R, Vissing J, Meisel A, ADAPT Study Group.   +10 more
europepmc   +1 more source

Immune checkpoint inhibitor-related kelch-like protein 11-IgG cerebellitis successfully treated with efgartigimod as rescue therapy: a case report. [PDF]

Front Immunol
Li YX, Ma ZM.
europepmc   +1 more source

Impact of Neonatal Fc Receptor on Transferrin Receptor Antibody Fusion Protein Pharmacokinetics. [PDF]

Pharmaceutics
Oyegbesan A, Jagadeesan N, Chandrashekar DV, Sumbria RK.   +3 more
europepmc   +1 more source